Novo Nordisk received SFDA approval for its latest diabetes drug, Victoza®, an injected treatment for type 2 diabetes. Victoza is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue approved in China. Novo Nordisk said it will launch the drug in the second half of 2011. The drug's main competitor will be another GLP-1 agonist, Byetta, a diabetes treatment that Lilly brought to China in 2009. More details....

Stock Symbols: (NYSE: NVO)  (NYSE: LLY)

Share this with colleagues: